In Response:
The interpretation by Friedberg that the consensus panel's emphasis was "heavily biased in favor of antiemetic therapy" 1 is not consistent with the published guidelines: the panel affirms that reducing baseline risk factors are important and constitute effective strategies in reducing the risks for developing postoperative nausea and vomiting (PONV).
In the published consensus, 2 Guideline 1 recommends the assessment of risks for PONV. Guideline 2 outlines strategies to reduce the baseline risks. Among the recommendations include the use of regional anesthesia with local anesthetics as well as the use of local anesthetic infiltration to reduce intraoperative and postoperative opioid requirements. This is followed by Guideline 3, which discusses the options for antiemetic pharmacotherapy. The panel believes this is a logical sequence for managing patients to prevent PONV. Universal PONV Prophylaxis in General Anesthesia: Should We Consider Its Immediate Implementation?
To the Editor:
The recently published Guidelines for the Management of Postoperative Nausea and Vomiting 1 were accompanied by an Editorial suggesting that, given the high efficacy, low cost, and safety of antiemetics, they should be routinely administered prophylactically to all patients receiving general anesthesia, irrespective of their risk classification. 2 On the basis of clinical reports showing that ondansetron could interfere with the postoperative analgesic effect of tramadol, 3, 4 we conducted animal experiments, to assess if the clinically used antiemetics would interact with tramadol. Our results demonstrated the presence of functional antagonism between the antinociceptive effects of tramadol and ondansetron or droperidol, 5 whereas the combination of dexamethasone and tramadol was strongly synergistic. 6 Although antiemetics are safe and efficacious drugs, their mechanism of action implicates relevant physiological systems such as pain processing pathways in the CNS. Tramadol induces analgesia by activating -opioid receptors and inhibiting norepinephrine and 5-HT reuptake, thus implicating 5-HT 3 receptors, which are antagonized by ondansetron to induce the antiemetic effect.
Assuming that the likelihood to develop a pharmacodynamic drug interaction increases exponentially with the number of drugs administered, few drugs are completely innocuous when given perioperatively. We modestly argue that the approval of such a general recommendation should be subject to extensive debate.
